Bayer HealthCare and Druggability Technologies (DRGT) have entered into a multi-year collaboration under which Bayer will deploy DRGT's Super-API platform to support formulation efforts aimed at improving compound solubility and bioavailability.
DRGT's platform covers early compound screening to clinical formulation of candidate drugs and will be applied across a wide range of compounds hindered by low solubility and poor bioavailability. DRGT's Super-API platform aims to accelerate drug selection and successful development of novel drug candidates.
The agreement includes support and funding for the Super-API development platform application to Bayer compounds and DRGT anticipates contributing to the manufacture of Bayer's Super-API constructed compounds during clinical development and manufacture.
"This is an important collaboration for DRGT, and we are delighted to be working with Bayer, a global leader in the discovery and development of important and novel drugs that significantly improve treatment outcomes and the quality of life of patients," said Gabor Heltovics, DRGT's chief executive officer. "We believe that the application of our Super-API technology to the discovery and development portfolio of Bayer will help unlock the full potential of many drug candidates and can deliver clinically important benefits to patients. We are also convinced that this collaboration will bring substantial value and success to our company and our shareholders."